These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 29188387

  • 1. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
    Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, Kumagai S, Fukushima Y, Okubo Y, Hojo S, Kusano M.
    J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.
    Kinoshita Y, Hongo M, Kusano M, Furuhata Y, Miyagishi H, Ikeuchi S, RPZ Study Group.
    Intern Med; 2017 Jul; 56(10):1131-1139. PubMed ID: 28502925
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
    Fujimoto K, Hongo M, Maintenance Study Group.
    Intern Med; 2011 Jul; 50(3):179-88. PubMed ID: 21297318
    [Abstract] [Full Text] [Related]

  • 5. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y, Acid-Related Symptom Research Group.
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T, Hongo H, Kimura T, Kojima Y, Harada S, Ota K, Takeuchi N, Noguchi T, Inoue T, Murano M, Higuchi K.
    J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
    [Abstract] [Full Text] [Related]

  • 8. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
    Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ.
    Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
    [Abstract] [Full Text] [Related]

  • 9. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
    Fujiwara Y, Habu Y, Ashida K, Kusano M, Higuchi K, Arakawa T.
    Digestion; 2013 May; 88(3):145-52. PubMed ID: 24008338
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
    Tanabe T, Hoshino S, Kawami N, Hoshikawa Y, Hanada Y, Takenouchi N, Goto O, Kaise M, Iwakiri K.
    Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
    [Abstract] [Full Text] [Related]

  • 11. The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer: a randomized controlled trial.
    Nakamura M, Tahara T, Shiroeda H, Matsunaga K, Otsuka T, Yonemura J, Shibata T, Arisawa T.
    Hepatogastroenterology; 2015 Oct; 62(137):219-24. PubMed ID: 25911899
    [Abstract] [Full Text] [Related]

  • 12. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, Kojima Y, Sakamoto H, Kuramoto T, Kojima K, Sanomura M, Hoshimoto M, Higashino T, Itabashi T, Takada K, Sakaguchi M, Tominaga K, Kusano M, Higuchi K.
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

  • 16. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
    Suzuki T, Matsushima M, Masui A, Tsuda S, Imai J, Nakamura J, Tsukune Y, Uchida T, Yuhara H, Igarashi M, Koike J, Mine T.
    World J Gastroenterol; 2015 Apr 28; 21(16):5023-31. PubMed ID: 25945018
    [Abstract] [Full Text] [Related]

  • 17. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC, Lin JT, Wang HP, Chiu HM, Wu MS.
    J Gastroenterol Hepatol; 2007 Aug 28; 22(8):1286-92. PubMed ID: 17559380
    [Abstract] [Full Text] [Related]

  • 18. Healing erosive esophagitis with a proton pump inhibitor: the more the merrier?
    Fass R.
    Am J Gastroenterol; 2012 Apr 28; 107(4):531-3. PubMed ID: 22475962
    [Abstract] [Full Text] [Related]

  • 19. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
    Akahoshi T, Kawanaka H, Tomikawa M, Saeki H, Uchiyama H, Ikeda T, Shirabe K, Hashizume M, Maehara Y.
    Fukuoka Igaku Zasshi; 2013 Dec 28; 104(12):483-9. PubMed ID: 24693675
    [Abstract] [Full Text] [Related]

  • 20. [A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study].
    Jee SR, Seol SY, Kim DH, Park SJ, Han SY, Urm SH, Lee JT.
    Korean J Gastroenterol; 2005 May 28; 45(5):321-7. PubMed ID: 15908764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.